Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Quinazoline derivatives for the treatment of cancer diseases
US9539258B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9539258-B2 |
| Application number | US-201514739299-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 15, 2015 |
| Priority date | Nov 11, 2005 |
| Publication date | Jan 10, 2017 |
| Grant date | Jan 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the use of quinazolines of formula (I), wherein the groups R a to R d have the meanings given in the claims and specification, in cancer therapy.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating metastatic non-small cell lung cancer (NSCLC) of squamous histology in a second line patient having failed at least one prior chemotherapy regimen, the method comprising administering to said patient a therapeutically effective amount of the compound 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, or a physiologically acceptable salt thereof. 2. The method of claim 1 , wherein the 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, or a physiologically acceptable salt thereof, is used in monotherapy or in combination with another anti-tumour therapeutic agent. 3. The method of claim 2 , wherein the other anti-tumour therapeutic agent is selected from the group consisting topoisomerase inhibitors, mitosis inhibitors, compounds which interact with nucleic acids, hormone antagonists, inhibitors of metabolic processes, cytokines, and antibodies. 4. The method of claim 2 , wherein the other anti-tumour therapeutic agent is cis-platinum. 5. The method of claim 2 , wherein the compound is 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title
- A61K31/517Primary
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title
Heavy metals; Compounds thereof · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9539258B2 cover?
- The present invention relates to the use of quinazolines of formula (I), wherein the groups R a to R d have the meanings given in the claims and specification, in cancer therapy.
- Who is the assignee on this patent?
- Boehringer Ingelheim Int
- What technology area does this patent fall under?
- Primary CPC classification A61K31/517. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).